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a  b  s  t  r  a  c  t
Objectives: Progression of hepatic ﬁbrosis is accelerated in patients co-infected with human
immunodeﬁciency  virus and hepatitis C virus compared to hepatitis C virus mono-infected
patients.  This study aimed to compare ultrasound features and selected clinical and bio-
chemical  variables between patients with human immunodeﬁciency virus/hepatitis C virus
co-infection (n = 16) versus hepatitis C virus mono-infection (n = 16).
Methods: Each patient underwent abdominal ultrasound, and a speciﬁc evaluation was per-
formed in order to detect ﬁndings consistent with chronic liver disease. Characterization of
spleen size, liver structural pattern, diameter of the portal, spleen, and mesenteric veins was
based on classical ultrasound parameters. Propensity score was used for control of selection
bias  and performed using binary logistic regression to generate a score for each patient. The
Fisher and Mann–Whitney tests were used to evaluate categorical variables and continuous
variables,  respectively.
Results:  On univariate analysis right hepatic lobe size was larger in human immuno-
deﬁciency  virus/hepatitis C virus patients (157.06 ± 17.56 mm) compared to hepatitis C
virus  mono-infected patients (134.94 ± 16.95 mm) (p = 0.0011). The left hepatic lobe was
also  signiﬁcantly larger in human immunodeﬁciency virus/hepatitis C virus patients
(115.88  ± 22.69 mm) versus hepatitis C virus mono-infected patients (95.06 ± 24.18 mm)
(p  = 0.0177). Also, there was a strong correlation between hepatomegaly and co-infection
(p  = 0.005).
Conclusion: Human immunodeﬁciency virus infection was the primary variable inﬂuenc-
ing  liver enlargement in this population. Hepatomegaly on ultrasound was more  common
among  cirrhotic human immunodeﬁciency virus/hepatitis C virus co-infected patients thanamong cirrhotic hepatitis
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(1)  portal vein diameter larger than 12 mm;  (2) mesenteric andb r a z j i n f e c t d i s .
ntroduction
hronic hepatitis is one of the most relevant co-morbidities
f  patients co-infected with human immunodeﬁciency virus
HIV)  and hepatitis C virus (HCV).1 HIV-infected patients are
t  increased risk for HCV infection, with an estimated HCV
revalence  of 30–35% in this population.1 Among HIV-positive
rug  users, the reported prevalence of HCV is up to 80%.2,3
atients co-infected with HIV and HCV develop liver disease
ore  rapidly, and earlier progression to liver cirrhosis has been
escribed in this population.4–7
Liver cirrhosis is usually suspected on the basis of abnor-
alities in standard liver function, biochemical (blood) tests,
on-invasive  methods of evaluating ﬁbrosis, and ultrasound
US)  examination. The role of radiology in the evaluation of
iver  cirrhosis is primarily to characterize the morphologic
anifestations of the disease, evaluate hepatic and extra-
epatic  vasculature, assess the effects of portal hypertension,
nd  detect liver tumors.
There  are scarce data in the literature regarding US stud-
es  in HIV/HCV co-infected patients, particularly those with
iver  cirrhosis. US ﬁndings could inﬂuence the management
f  these patients in terms of identifying indications for liver
iopsy,  treatment, and surveillance for hepatocellular carci-
oma.
The  aim of this case–control study was  to compare US fea-
ures  and selected clinical and biochemical variables among
IV/HCV  co-infected versus HCV mono-infected patients with
epatic  cirrhosis matched for age, gender, and body mass
ndex  (BMI). We  aimed to answer two questions: (1) Is there any
ifference in liver size between co-infected and mono-infected
irrhotic patients? (2) Are there demographic and clinical vari-
bles  related to liver size?
ethods
tudy  population
he initial study population was  45 patients, including 28
IV/HCV  co-infected and 17 HCV mono-infected patients. We
pplied a propensity score using three demographic char-
cteristics (age, gender, and BMI) and identiﬁed 16 patients
ith  HIV/HCV co-infection (study group) and 16 patients with
CV  mono-infection (control group). The co-infected patients
ere  selected among patients seeking regular care at the
IDS  Outpatient Clinic of the Hospital das Clínicas, Medi-
al  School, Universidade de São Paulo. HCV mono-infected
atients were  selected from those registered at the Depart-
ent  of Gastroenterology, Universidade de São Paulo School of
edicine.  Patients were  selected from January 2006 to January
007.
All  patients had a diagnosis of HCV infection (seropositive
or HCV-RNA) and a histopathological diagnosis of liver cir-
hosis.  Each patient underwent abdominal US, and a speciﬁc
valuation was  performed in order to detect ﬁndings consis-
ent  with chronic liver disease (liver and spleen size, liver
exture,  diameter of the portal, splenic, and superior mesen-
eric  veins). We  analyzed the following additional variables:
istory  of high ethanol consumption (daily intake of more3;1 7(2):150–155  151
than 60 g for females or more  than 80 g for males for more  than
10  years), HCV genotype, US parameters, and the presence of
steatosis  on liver biopsy.
Patients  were excluded if they had a history of chronic liver
disease  from other etiology (including hepatitis B virus co-
infection),  opportunistic infections, or other serious medical
conditions.
Liver  biopsy
Liver biopsy was  indicated in all subjects to evaluate the sever-
ity  of hepatic disease. The decision to proceed with a liver
biopsy  was  made during routine work-up for chronic hepati-
tis  C, and was  in accordance with accepted clinical practice by
physicians stafﬁng the Department of Gastroenterology and
Infectious  Diseases at the University of São Paulo School of
Medicine.  Steatosis on liver biopsies was graded according to
the following categories: 0 (minimal, <5%), 1 (mild, 5–33%), 2
(moderate,  34–66%), or 3 (severe, >66%). Biopsy was  performed
at  a mean of 12 (standard deviation [SD] 3.6) months after US
examination.
Ultrasound  examination
All patients underwent US of the abdomen. The opera-
tor  was  an experienced US examiner and was  blinded to
other  patient variables. Patients were in the supine posi-
tion  for all examinations. For better access to the liver,
patients were instructed to raise their hands behind the
head,  thus increasing the intercostal spaces and the distance
from  the lower costal margin to the iliac crest. US exami-
nation was performed during deep inspiration and with a
relaxed  abdominal wall. In each case, the liver was  examined
and  visualized in three planes: longitudinal, cross-sectional,
and diagonal. Patients fasted for an average of 6 h prior to
US.
A  speciﬁc protocol was  performed to evaluate the charac-
teristics consistent with chronic liver disease (liver and spleen
size,  liver texture, diameter of the portal, splenic, and mesen-
teric  veins). The right hepatic lobe size was  measured in
accordance to prior research: the cranio-caudal diameter was
determined  in the conventional section in the mid-clavicular
line, by measuring from the hepatic dome to the inferior
hepatic tip.8–10 The left hepatic lobe was measured at the
median line of the abdomen, parallel to the aorta.
Normal liver size was  deﬁned as follows: in men  with
BMI  between 22 and 26 kg/m2 and women with BMI between
22  and 25 kg/m2, normal liver size was 13.5 ± 1.7 cm;  in men
with  BMI > 26 kg/m2 and women  with BMI > 25 kg/m2, normal
liver  size was 14.5 ± 1.7 cm.10 Characterization of other fea-
tures  (spleen size, liver structural pattern, diameter of the
portal,  spleen, and mesenteric veins) was based on classical
US  parameters.11
Portal hypertension was deﬁned by the following criteria:splenic  veins larger than 9 mm;  (3) the presence of collateral
routes;  and (4) spleen index larger than 20 cm2 [9]. Liver steato-
sis  was  deﬁned on US by the observation of a bright liver echo
pattern  or by the loss of portal venous walls.12
















Fig. 1 – Box plot of right hepatic lobe (RHL) measurement in
HCV  (n = 16) and HIV/HCV (n = 16) infected patients. Bars
represent minimum and maximum sizes recorded.
liver  cirrhosis. This is a notable ﬁnding, as most patients with
cirrhosis  have smaller livers than non-cirrhotic patients with
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Clinical  and  viral  variables
Medical records were  retrospectively reviewed to ascertain
demographic and clinical characteristics, and to obtain lab-
oratory  data preceding the US examination. An electronic and
written  database containing information on all patients was
used  as the source of laboratory information. On the day of
the  US examination, measurements of body weight and height
were  performed in a standardized fashion by clinical research
coordinators.
The  local Ethics Committee reviewed and approved this
study.  All patients who participated in the study provided
informed consent.
Statistical  analysis
Propensity score was  used for control of selection bias and per-
formed  using binary logistic regression to generate a score for
each patient (study cases and controls). Variables included in
the propensity model were  age, gender, and BMI. The Fisher
Exact  Test was  used to verify associations between categorical
variables. The Mann–Whitney test was  used to evaluate con-
tinuous  variables. p-Values <0.05 were considered statistically
signiﬁcant.
Results
Most patients were  male (14 in each group [87.5%]). Mean age
was  45.19 ± 6.48 years in the co-infected group and 48.13 ± 4.44
years in the mono-infected group (p = 0.1453).
On univariate analysis, right hepatic lobe size was  larger
in  HIV/HCV co-infected cirrhotic patients (157.06 ± 17.56 mm)
compared  to HCV mono-infected cirrhotic patients
(134.94 ± 16.95 mm)  (p = 0.0011). The left hepatic lobe was
also  signiﬁcantly larger in HIV/HVC co-infected patients
(115.88 ± 22.69 mm)  versus HCV mono-infected patients
(95.06 ± 24.18 mm)  (p = 0.0177). Hepatomegaly on US was  more
common  among HIV/HCV co-infected patients compared to
HCV mono-infected patients. Figs. 1 and 2 show box plots of
the  right and left hepatic lobes size, respectively, in the mono-
and  co-infected groups.
To  categorize hepatomegaly we adopted a cut-off for the
right  lobe of 152 mm,  as described by Kratzer et al.10 We then
used  the Fisher Exact Test and found a signiﬁcant correlation
between hepatomegaly and co-infection (p = 0.005). We found
no  association between hepatomegaly and HCV genotype 3
versus non-3 (p > 0.999).
On univariate analysis, there was  no signiﬁcant differ-
ence  in the diameter of portal (p = 0.783), superior mesenteric
(p  = 0.5079), or splenic veins (p = 0.5578) between groups.
Spleen size was  also similar in both groups (p = 0.6978).
Table 1 summarizes US liver steatosis grades of HIV/HCV
co-infected patients versus HCV mono-infected patients.
There  was  no difference between groups in terms of US ﬁnd-
ings  of steatosis.
All  patients had a histopathological diagnosis of cirrho-
sis.  There was  no signiﬁcant difference between groups in the
degree  of steatosis by histology (p > 0.05).Horizontal line represents the median value.
On univariate analysis, there was  no signiﬁcant difference
between groups according to ethanol consumption.
Discussion
Liver enlargement has been previously observed on abdominal
US  in HIV-infected patients.13–15 We performed the cur-
rent  investigation to determine if HIV and HCV co-infection
produces different pathologic ﬁndings. We found that some
patients  with HIV/HCV co-infection had larger livers than
mono-infected patients, even in the presence of establishedFig. 2 – Box plot of left hepatic lobe (LHL) measurement in
HCV  (n = 16) and HIV/HCV (n = 16) infected patients. Bars
represent minimum and maximum sizes recorded.
Horizontal line represents the median value.
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Table 1 – Demographic, ultrasonographic, and histologic characteristics of the study population.
HIV/HCV HCV p-value
Age (years) 45.19 ± 6.48 48.13 ± 4.44 0.145
Male gender (%) 87.5 87.5 >0.999
BMI (kg/m2) 23.85 ± 3.40 25.73 ± 3.91 0.156
High ethanol consumption (%) 45.45 31.25 0.686
HCV genotype 3 (%) 58.33 18.75 0.049
HCV genotype 1 (%) 41.66 68.75
HCV genotype 2 (%) 0 12.5
Right hepatic lobe (mm) 157.06 ± 17.56 134.94 ± 16.95 0.001
Left hepatic lobe (mm) 115.88 ± 22.69 95.06 ± 24.18 0.017
Steatosis grade on ultrasound
Mild  (%) 6.25 12.5 >0.999
Moderate (%) 6.25 6.25
High (%) 18.75 12.5
Steatosis grade on liver histology
0  (%) 50.0 37.5 0.697
1 (%) 31.25 37.5
2 (%) 6.25 18.75


































aBMI, body mass index.
hese patients for treatment and surveillance. The main goal
f  this study was  to determine if HIV/HCV co-infected patients
ad  enlarged livers compared to HCV mono-infected patients.
o  evaluate this hypothesis we designed a case–control study
ncluding  16 patients with HIV/HCV co-infection and 16
atients  with HCV mono-infection, with groups paired using
ropensity  score. The two groups were similar according to
ge,  gender, and BMI. We  analyzed some demographic, clin-
cal,  and US variables, including right and left hepatic lobe
ize,  spleen size, and portal, superior mesenteric, and splenic
ein  measurement on US examination, ethanol consump-
ion,  HCV genotype, and grade of steatosis on liver biopsy.
atients were  excluded if they had a history of chronic liver
isease  from another etiology (including hepatitis B virus co-
nfection), opportunistic infections, or other serious medical
onditions.
We  found that co-infected patients had signiﬁcantly larger
ivers  than mono-infected patients on univariate analysis. To
etermine the inﬂuence of other factors on liver size, we
nalyzed  demographic and clinical variables; on univariate
nalysis there was  no signiﬁcant association between liver
ize  and ethanol consumption, liver steatosis, and HCV geno-
ype.  Many  other factors may  inﬂuence liver size in these
atients;  it was  not the objective of this study to identify all
igniﬁcant  features related to liver size, but we  did conﬁrm
hat  the presence of HIV infection was  the main difference
etween the two groups.
Fat  inﬁltration of the liver can cause hepatomegaly.16 In
ur  patient population, steatosis might play a role in liver
nlargement. HCV itself can result in fat deposition in the
iver17 and in patients with chronic hepatitis C, steatosis
s  associated with genotype 3, probably by promoting the
roduction  of lipid-rich VLDL that facilitates maturation
f  HCV precursors by optimizing HCV replication and thus
ontributing to steatosis.18–21 We did not ﬁnd a signiﬁcant
ssociation between hepatomegaly and HCV genotype 3.Liver  steatosis was  not more  common in patients with
larger  hepatic size, thus we could not identify an association
between HCV genotype 3 and hepatomegaly in the co-infected
group.  The presence of HIV infection was the main factor we
found  differentiating smaller versus larger cirrhotic livers.
The  etiology of steatosis in patients with HIV-HCV co-
infection is indeed multifactorial. Therefore, we  speculate
that  HIV-infected patients with chronic hepatitis C caused
by  HCV-3 who are taking antiretroviral therapy may  be par-
ticularly  prone to developing liver steatosis and more  severe
liver  ﬁbrosis. The rising rates of diabetes and obesity among
HIV-infected patients22,23 similar to the general US popula-
tion,  may  also contribute to non-alcoholic fatty liver disease
(NAFLD)  in this patient group. In addition, studies suggest
that  gut-derived lipopolysaccharides may  promote hepatic
damage.24
Ethanol ingestion and the use of antiretroviral drugs
(particularly nucleoside analogs) are often reported to
cause  liver steatosis.25 HIV is associated with changes in
lipid  metabolism, as well as with the development of
metabolic syndrome with lipoatrophy or lipodystrophy, dys-
lipidemia,  peripheral insulin resistance, and increased hepatic
steatosis.26
When we evaluated right hepatic lobe size, measured at
the  mid-clavicular line, we  found co-infected patients to have
larger  sizes compared to mono-infected patients (p = 0.0011). A
recent study of age-related changes in abdominal organ struc-
ture  and function with computed tomography and positron
emission tomography showed that the liver enlarges in child-
hood,  but we clearly see a continued size increase up to 49
years  of age, when the organ volume achieves 1606 mL  (18–49
years)  and then diminishes to 1467 mL  (50–81 years).27 We  did
not  evaluate the effect of age on hepatic size because we  used
age-matched  controls for comparison.
In general, diagnostic imaging techniques are claimed
to  be superior to clinical examination in determining liver
i s . 2 0
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size.28,29 Nevertheless, there is a paucity of data regarding
normal and borderline values, and no uniform procedure
for  measuring the size of the liver has been established that
can  serve as a guideline for US examination.30 In a study
published by Gosink and Leymaster,30 data regarding liver
specimens obtained at autopsy correlated with anthropomet-
ric  data of the same patient, and this correlation was  used to
diagnose  hepatomegaly.
It  must be highlighted that the estimation of liver size
on  the basis of a single parameter, such as liver diame-
ter  in the right mid  clavicular line, is limited, considering
the range of liver morphotypes.31 Obesity, accumulation of
abdominal  gas, and uncooperative patients (lack of coordina-
tive  respiration) are other known limitations of this method.
Despite  these facts, the evaluation of hepatic size is a fre-
quent  issue in abdominal US (especially for the determination
of  hepatomegaly), and this method complements physical
examination.29 When we evaluated the left lobe, we  per-
formed  the same analysis as with the right lobe, with similar
results.  The common ﬁnding of left lobe enlargement in liver
disease  helps to overcome the limitations of clinical exami-
nation,  although left lobe measurement is often inaccurately
performed and is not standardized for routine US.
To  the best of our knowledge, the present study is the ﬁrst to
report  enlargement of cirrhotic livers in HIV/HCV co-infected
patients. In general, the most common US features in patients
with  cirrhosis are the presence of irregularity (irregular sur-
face  and liver nodules)32 and liver atrophy. In more  advanced
stages of liver disease, the liver becomes small with a multin-
odular  surface, decreased portal blood ﬂow can be observed
by  Doppler, and eventually ascites can be detected. Unlike
patients  with cirrhosis of viral origin, patients with cirrhosis
of  alcoholic origin and non-alcoholic fatty liver disease may
have  hepatomegaly on clinical or imaging evaluation.33,34
The ﬁnding that hepatomegaly was  a common US fea-
ture  among cirrhotic HIV/HCV co-infected patients may  have
important  implications. In clinical practice, US is currently
used  to predict the presence of cirrhosis in two general ways.
The  ﬁrst is by determining the presence or absence of portal
hypertension, and the second is by examining the size, lobar
ratios,  echogenicity, and echotexture of the liver.32 Although
the  signs of portal hypertension are usually recognized, in the
absence  of other clinical or image  abnormalities suggestive of
cirrhosis,  isolated liver enlargement may  be misdiagnosed by
clinicians as evidence of other clinical conditions related to
HIV  infection and unrelated to cirrhotic liver disease. Under
these  circumstances, diagnostic and therapeutic procedures
related  to the speciﬁc liver condition may  be postponed, with
inevitable  consequences to the patient.
This study had some limitations. First, liver biopsies were
not  performed at the same time as the US examinations.
Second, laboratory data concerning serum triglycerides, total
cholesterol,  high density lipoprotein, and fasting glucose lev-
els  were  not always collected during the 30 days preceding
the  US examination or liver biopsy. Therefore, we could not
evaluate  the association between serum metabolic and non-
invasive  ﬁbrosis evaluation tests and liver enlargement. These
limitations  may  have contributed to the fact that no associa-
tion  was  observed between liver enlargement and presence of
liver  steatosis on biopsy.
1 1 3;1  7(2):150–155
Conclusions
In conclusion, the presence of HIV infection was  the primary
variable  inﬂuencing liver enlargement in this population.
Hepatomegaly was  a more  common US feature among cir-
rhotic  HIV/HCV co-infected patients than among cirrhotic
HCV  mono-infected patients. This aspect could be important
in  the management of HIV/HCV co-infected patients, because
screening  for hepatocellular carcinoma is necessary in this
population.
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